2c:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/1bqb83_yclja0.js","/_next/static/immutable/chunks/1on664om2hmh1.js","/_next/static/immutable/chunks/30t4sjq-27eg7.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2d:T6a8a,

FEATURE	DETAIL
Risk Factors	Female sex (oligoarticular and polyarticular subtypes), age younger than 16, HLA-B27 positivity (enthesitis-related subtype), family history of autoimmune disease, ANA positivity (risk factor for uveitis)
Etiology	Autoimmune process of unknown cause; genetic predisposition combined with environmental triggers leading to chronic synovial inflammation
Patient Presentation	Joint pain, swelling, and morning stiffness lasting more than 6 weeks in a child younger than 16; systemic subtype presents with daily spiking fevers and rash
Classic Physical Exam	Warm, swollen joint (commonly the knee) with limited range of motion; salmon-colored, evanescent (comes and goes), macular rash in systemic subtype; leg-length discrepancy in chronic oligoarticular disease
Key Diagnostic Results	Elevated ESR and CRP; positive ANA (oligoarticular); positive RF (polyarticular RF-positive subtype); markedly elevated ferritin in systemic subtype; slit-lamp exam may reveal anterior uveitis
Management	NSAIDs as initial therapy; intra-articular corticosteroid injections for oligoarticular disease; methotrexate as first-line DMARD; biologic agents (anti-TNF, IL-1, or IL-6 inhibitors) for refractory cases; routine ophthalmologic screening for uveitis
Keywords	"Morning stiffness improving with activity," "quotidian fever," "salmon-colored evanescent rash," "limp in a child with swollen knee," "painless red eye" (uveitis), "ANA-positive young girl with knee swelling"

1. Pathophysiology

Juvenile Idiopathic Arthritis is a group of chronic arthritides defined by the onset of arthritis before age 16 that persists for at least 6 weeks with no other identifiable cause. The disease results from a dysregulated immune response where autoreactive T cells and pro-inflammatory cytokines attack the synovial membrane. This triggers synovial hypertrophy and pannus formation, which is the same destructive tissue seen in adult rheumatoid arthritis.

The inflamed synovium produces excess synovial fluid, explaining the joint effusion and swelling seen on exam. Ongoing inflammation erodes cartilage and underlying bone over time, which accounts for the joint space narrowing and bony erosions visible on late-stage imaging. Morning stiffness occurs because inflammatory cytokines accumulate in the joint overnight during immobility; once the child begins moving, the fluid redistributes and stiffness improves. This pattern of "stiffness that gets better with activity" (also called a gelling phenomenon) is the hallmark that distinguishes inflammatory arthritis from mechanical joint disease.

In the systemic subtype, the pathophysiology is driven predominantly by the innate immune system rather than adaptive immunity. Macrophage activation leads to overproduction of IL-1 and IL-6, which cause the characteristic daily spiking (quotidian) fevers, hepatosplenomegaly, and serositis. This innate immune overdrive also explains why systemic JIA responds poorly to methotrexate (which targets adaptive immunity) and instead responds to IL-1 and IL-6 blockade. A feared complication of systemic JIA is macrophage activation syndrome (MAS), a life-threatening cytokine storm characterized by paradoxically falling ESR, skyrocketing ferritin, pancytopenia, and liver dysfunction.

In the oligoarticular subtype, chronic anterior chamber inflammation leads to uveitis, which is often asymptomatic ("white and quiet" eye). The mechanism involves autoreactive T cells targeting ocular antigens in the anterior uveal tract. Because the eye is not painful or red in most cases, uveitis can progress silently to synechiae, band keratopathy, and vision loss if slit-lamp screening is not performed.

2. Classification and Clinical Manifestation

The international classification recognizes several subtypes, each with distinct demographics, joint patterns, and extra-articular features. Distinguishing subtypes is critical because management and prognosis differ.

SUBTYPE	TYPICAL PATIENT	JOINT PATTERN	EXTRA-ARTICULAR FEATURES	KEY LAB FINDINGS
Oligoarticular (persistent)	Young girl, age 2 to 6	4 or fewer joints; large joints predominate (knee is most common)	Anterior uveitis (high risk if ANA-positive)	ANA positive in up to 70 to 80%; RF negative
Oligoarticular (extended)	Same demographic as persistent	Begins with 4 or fewer joints, then extends to 5 or more after 6 months	Same uveitis risk	ANA positive; RF negative
Polyarticular, RF-negative	Girls, bimodal age distribution (early childhood and late childhood)	5 or more joints; symmetric; small and large joints	Uveitis (lower risk than oligoarticular); low-grade fever	ANA may be positive; RF negative
Polyarticular, RF-positive	Adolescent girls	5 or more joints; symmetric small joints of hands and feet	Rheumatoid nodules; aggressive erosive disease resembling adult RA	RF positive; anti-CCP may be positive
Systemic (Still disease)	Boys and girls equally; any age in childhood	Variable; may have no arthritis at onset	Quotidian fever, salmon-colored evanescent rash, lymphadenopathy, hepatosplenomegaly, serositis, MAS risk	Markedly elevated ferritin, leukocytosis, thrombocytosis, elevated ESR and CRP; ANA and RF typically negative
Enthesitis-related arthritis	Older boys, age older than 6	Lower extremity large joints; sacroiliac joint; axial skeleton	Enthesitis (Achilles, plantar fascia), acute anterior uveitis (symptomatic, painful, and red), inflammatory bowel disease association	HLA-B27 positive; ANA and RF negative
Psoriatic arthritis	Bimodal; younger girls and older boys	Asymmetric; may involve small joints; dactylitis ("sausage digits")	Psoriatic skin lesions, nail pitting, dactylitis	ANA may be positive in younger patients

The quotidian fever of systemic JIA is one of the most recognizable patterns on an exam vignette. The temperature spikes to 39 degrees Celsius or higher once or twice daily (classically in the late afternoon or evening) and then returns to normal or below normal between spikes. The salmon-colored rash is evanescent, meaning it appears during febrile episodes and fades when the fever resolves, often provoked by a warm bath (Koebner phenomenon).

3. Diagnostic Workup

TEST	PURPOSE	EXPECTED FINDINGS
ESR and CRP	Assess systemic inflammation	Elevated in active disease; may be paradoxically low or dropping in MAS
Complete blood count	Screen for cytopenias (MAS) and leukocytosis (systemic JIA)	Leukocytosis and thrombocytosis in systemic JIA; pancytopenia suggests MAS
ANA	Risk-stratify for uveitis	Positive in oligoarticular and some polyarticular subtypes; guides screening frequency
RF and anti-CCP	Classify polyarticular subtype	Positive RF and/or anti-CCP identifies the RF-positive polyarticular subtype
HLA-B27	Support enthesitis-related arthritis classification	Positive in enthesitis-related arthritis
Ferritin	Screen for MAS in systemic JIA	Very high ferritin (often above 10,000 ng/mL in MAS); disproportionately elevated relative to ESR
Slit-lamp examination	Screen for anterior uveitis	Cells and flare in the anterior chamber; may be entirely asymptomatic
Plain radiographs	Baseline joint assessment	Soft tissue swelling and effusion early; joint space narrowing, erosions, and periarticular osteopenia late
MRI with contrast	Detect early synovitis and cartilage damage	Synovial enhancement, effusion, bone marrow edema, early erosions not visible on X-ray
Joint aspiration	Exclude septic arthritis when presentation is acute	Inflammatory fluid (elevated WBC, predominantly lymphocytes); negative Gram stain and culture

JIA is a clinical diagnosis. There is no single confirmatory lab test. The diagnosis requires arthritis in a patient younger than 16, lasting at least 6 weeks, with exclusion of other causes (infection, malignancy, connective tissue disease, reactive arthritis). The role of lab tests is to classify the subtype and screen for complications, not to confirm the diagnosis itself.

The best initial step when a child presents with chronic joint swelling is a thorough history and physical examination combined with basic inflammatory markers (ESR, CRP, CBC). ANA and RF are then ordered to classify the subtype and risk-stratify for uveitis.

When the presentation is acute monoarthritis (a single hot, swollen joint), the most critical first step is to rule out septic arthritis. Joint aspiration with Gram stain, culture, and cell count must be performed before attributing the findings to JIA. A septic joint is a surgical emergency and cannot be missed.

Slit-lamp examination is mandatory for all newly diagnosed JIA patients. The frequency of follow-up screening depends on the subtype, ANA status, and age at onset. ANA-positive children with oligoarticular JIA younger than 7 at onset are at the highest risk and require slit-lamp exams every 3 months. Uveitis in JIA is typically chronic, bilateral, and anterior. It is usually asymptomatic in oligoarticular and polyarticular subtypes (unlike the painful, red, acute uveitis seen in enthesitis-related arthritis).

MRI is the most sensitive imaging modality for detecting early synovitis, cartilage loss, and bone marrow edema before radiographic changes appear. It is not required for diagnosis but is used when clinical assessment is uncertain or to evaluate disease activity and damage in complex cases.

If systemic JIA is suspected and the child deteriorates with falling blood counts, falling ESR, rising ferritin, rising liver enzymes, and rising triglycerides, the diagnosis of MAS must be considered immediately. The hallmark laboratory triad of MAS is markedly elevated ferritin with paradoxically falling ESR and new cytopenias. A ferritin-to-ESR ratio that is disproportionately high should raise concern.

4. Management and Treatment

INTERVENTION	INDICATION	KEY DETAILS
NSAIDs (naproxen, ibuprofen)	First-line for all subtypes; symptom control	Naproxen 10 to 20 mg/kg/day divided twice daily; ibuprofen 30 to 40 mg/kg/day divided three to four times daily; max 6 to 8 weeks trial before escalation
Intra-articular corticosteroid injection (triamcinolone hexacetonide)	Oligoarticular JIA; bridging therapy	Triamcinolone hexacetonide preferred over acetonide for longer-lasting effect; can be repeated but generally limited to 3 to 4 injections per joint per year
Methotrexate	First-line DMARD for polyarticular JIA, extended oligoarticular, or NSAID-refractory disease	10 to 15 mg/m2 once weekly (oral or subcutaneous); supplement with folic acid 1 mg daily; monitor CBC and liver function every 1 to 3 months; teratogenic, requires contraception counseling in adolescents
Anti-TNF biologics (etanercept, adalimumab)	Methotrexate-refractory polyarticular JIA	Etanercept 0.8 mg/kg subcutaneously once weekly (max 50 mg); adalimumab 24 mg/m2 subcutaneously every 2 weeks; screen for tuberculosis before initiation
Adalimumab or infliximab	JIA-associated uveitis refractory to methotrexate	Adalimumab preferred for uveitis; etanercept is less effective for ocular disease
IL-1 inhibitors (anakinra, canakinumab)	Systemic JIA	Anakinra 1 to 2 mg/kg/day subcutaneously (may increase to 4 mg/kg/day); canakinumab 4 mg/kg subcutaneously every 4 weeks; target the innate immune pathway driving systemic inflammation
IL-6 inhibitor (tocilizumab)	Systemic JIA; polyarticular JIA	Tocilizumab 8 to 12 mg/kg intravenously every 2 weeks (systemic) or 8 mg/kg every 4 weeks (polyarticular); monitor for hepatotoxicity and neutropenia
Systemic corticosteroids	Bridging therapy in severe systemic JIA; MAS	Prednisone 1 to 2 mg/kg/day; pulse IV methylprednisolone for MAS; taper as biologic therapy takes effect; avoid long-term use due to growth suppression
Physical therapy and occupational therapy	All patients	Maintain joint range of motion; prevent contractures and muscle atrophy; ongoing throughout disease course

Acute management begins with NSAIDs for symptom relief. For oligoarticular disease with one or two involved joints, intra-articular corticosteroid injection is often the most effective early intervention and may be sufficient as monotherapy for persistent oligoarticular JIA. Triamcinolone hexacetonide is preferred because it provides longer duration of remission compared to triamcinolone acetonide.

If the disease involves five or more joints, or if the oligoarticular subtype extends beyond four joints, methotrexate becomes the cornerstone of treatment. It is given once weekly, not daily. Folic acid supplementation reduces side effects (oral ulcers, nausea, hepatotoxicity) without diminishing efficacy. Methotrexate is teratogenic (Category X) and must be accompanied by strict contraception counseling in adolescent females. Baseline and periodic monitoring of liver enzymes, CBC, and renal function is required.

When methotrexate fails or is not tolerated, biologic therapy is added. For polyarticular subtypes, anti-TNF agents (etanercept or adalimumab) are the standard next step. Tuberculosis screening with a PPD or interferon-gamma release assay is mandatory before starting any anti-TNF agent, because TNF blockade can reactivate latent tuberculosis. For JIA-associated uveitis, adalimumab is preferred over etanercept; etanercept has been shown to be less effective in controlling ocular inflammation.

For systemic JIA, the treatment paradigm differs. Because the disease is driven by IL-1 and IL-6 rather than by adaptive immunity, methotrexate and anti-TNF agents are often ineffective. IL-1 inhibitors (anakinra or canakinumab) or IL-6 inhibitors (tocilizumab) are the targeted therapies of choice. Systemic corticosteroids are used for bridging in severe cases but should be tapered as soon as biologic therapy achieves disease control, given the adverse effects on growth and bone density in children.

MAS is treated as a medical emergency with high-dose intravenous methylprednisolone (30 mg/kg/day, max 1 g, for 3 consecutive days), followed by cyclosporine A if there is no rapid improvement. Anakinra at high doses has also shown benefit in refractory MAS. Early recognition and aggressive treatment are critical because MAS carries significant mortality.

5. Differential Diagnosis and Distractors

DIFFERENTIAL	WHY IT IS SIMILAR	KEY DISCRIMINATOR
Septic arthritis	Acute monoarthritis with a warm, swollen joint in a child	Septic arthritis presents with fever, inability to bear weight, and severely restricted motion; synovial fluid shows WBC above 50,000 with neutrophil predominance and positive culture; JIA is chronic (more than 6 weeks) and culture-negative
Acute rheumatic fever	Pediatric arthritis with fever and systemic symptoms; both are diagnoses of exclusion	Rheumatic fever causes migratory polyarthritis (moves from joint to joint), follows a group A streptococcal pharyngitis (elevated ASO titer), and is associated with carditis; JIA arthritis is additive (new joints are added while old ones remain involved)
Reactive arthritis	Post-infectious arthritis in a child	Reactive arthritis follows a GI or GU infection, is self-limited (usually resolves within weeks to months), and may present with the classic triad of arthritis, urethritis, and conjunctivitis; JIA persists beyond 6 weeks and lacks the preceding infection
Leukemia (ALL)	Bone and joint pain in a child with limping; may have elevated inflammatory markers	Leukemia causes bone pain (often nocturnal), unexplained bruising, pallor, hepatosplenomegaly, and blasts on peripheral smear; LDH and uric acid elevated; the child looks systemically unwell out of proportion to the joint findings
Lyme arthritis	Monoarthritis of the knee in a child; can be chronic	History of tick exposure or erythema migrans rash in an endemic area; positive Lyme serologies (ELISA followed by Western blot confirmation); JIA is serology-negative for Lyme
Systemic lupus erythematosus	Polyarthritis with ANA positivity in a young female	SLE presents with a malar rash, oral ulcers, photosensitivity, renal involvement (proteinuria, hematuria), and positive anti-dsDNA or anti-Smith antibodies; JIA typically lacks multisystem organ involvement beyond joints and eyes
Henoch-Schonlein purpura (IgA vasculitis)	Pediatric joint pain and systemic symptoms	HSP presents with palpable purpura on the buttocks and lower extremities, abdominal pain, and possible renal involvement (IgA nephropathy); arthritis is non-erosive and self-limited
Osteomyelitis	Limping child with localized pain and fever	Pain is localized to the metaphysis of a long bone rather than the joint; MRI shows bone marrow changes rather than synovitis; blood cultures may be positive

The two most commonly tested distractors are septic arthritis (for acute presentations) and acute leukemia (for subacute presentations with systemic symptoms). Always consider malignancy when a child presents with bone or joint pain, especially if there is nocturnal pain, pancytopenia, or lymphadenopathy that seems disproportionate.

6. Traps and High-Yield Pearls

The single most common trap with JIA questions involves uveitis screening. Students either forget that uveitis is frequently asymptomatic or fail to identify which patients need the most aggressive screening. The child will not complain of eye pain or redness in the oligoarticular and polyarticular subtypes. The vignette may describe a young ANA-positive girl with knee arthritis who has been doing well, followed by a question about the "most appropriate next step." The answer is slit-lamp examination, not more joint imaging or a change in arthritis therapy. Missing uveitis leads to permanent vision loss, and exam writers test whether you understand that screening must be proactive rather than symptom-driven.

A second common error is confusing the fever pattern in systemic JIA with that of an infectious process. The quotidian fever of systemic JIA spikes high and returns to baseline or below between episodes, which differs from the persistent or remittent fevers of sepsis or endocarditis. The salmon-colored rash that appears with fever and vanishes between episodes is the discriminating clue.

Third, students frequently miss MAS when a child with systemic JIA suddenly deteriorates. The trap is the falling ESR. In most inflammatory conditions, worsening disease means rising ESR. In MAS, the ESR drops because fibrinogen is consumed (and ESR depends on fibrinogen). A dropping ESR with a rising ferritin in a sick child with systemic JIA should immediately suggest MAS, not clinical improvement.

Finally, remember that the joint pattern matters for classification: migratory arthritis points to rheumatic fever, while additive arthritis (joints accumulate rather than move) points to JIA. When the vignette describes arthritis that "moves from one joint to another," think rheumatic fever. When it describes progressively more joints becoming involved over weeks, think JIA.

The core competency being tested in JIA questions is the ability to classify the subtype based on the clinical vignette (joint count, age, sex, lab profile), select the appropriate management tier (NSAIDs, intra-articular steroids, methotrexate, or biologics), and recognize the silent complications (uveitis, MAS) that require proactive screening and urgent intervention.

1d:["$","$L2c",null,{"article":{"id":"f83b0840-088b-49fe-8e4e-58fc6fa12bc9","title":"Juvenile Idiopathic Arthritis","content":"$2d","category":"Muskuloskeletal","created_at":"2026-09-05T16:13:03.07802+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]